{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'The Treatment Cycle can start at the latest on Day 127 and can be completed within the', 'timeframe of the trial (26 weeks) AND', 'In case the patient was an MG-ADL responder at the previous Treatment Cycle: if he/she', 'has lost the response.', 'Loss of response is defined as a patient who no longer shows a decrease of at least', '2 points on the total MG-ADL score compared to the corresponding TCB.', 'However, patients may not receive re-treatment with ARGX-113 or placebo if, at the time of', 're-treatment, patients have clinical evidence of bacterial, viral or fungal disease, or any other', 'significant disease which could confound the results of the trial or put patients at undue risk.', 'Patients who are in need of an additional treatment but who are not eligible to receive re-', 'treatment for reasons listed here will remain in the trial to receive appropriate alternative MG', 'treatment. Re-treatment with IMP may be reconsidered at next time where conditions for', 're-treatment are met, providing that at least 4 weeks have past after other MG treatment (see', 'Appendix 9).', 'ROLL-OVER', 'At the EoS visit, patients will be offered the option to roll over into a long-term, single-arm,', 'open-label follow-on trial (ARGX-113-1705) where they will be treated with ARGX-113', '(10 mg/kg of body weight) on an \"as needed basis\".', 'Patients who need re-treatment but cannot complete a Treatment Cycle within the time frame', 'of the ARGX-113-1704 trial (i.e., require re-treatment after Day 127), may roll over', 'immediately to the follow-on trial to receive treatment with ARGX-113.', 'Patients who discontinue early from trial ARGX-113-1704, will not be offered the option to', 'roll over in the follow-on trial.', 'Patients who discontinue early from randomized treatment for rescue or pregnancy reasons or', 'for an SAE that is likely to result in a life-threatening situation or pose a serious safety risk', 'will also not be offered the option to roll over to the follow-on trial.', 'Patients who discontinue early from randomized treatment for other reasons and patients who', 'have a temporary interruption from randomized treatment may be offered the option to roll', 'over to the follow-on trial.', 'RESCUE THERAPY', 'Rescue therapy will be limited to PLEX, IVIg, immunoadsorption or use of a new type of', 'corticosteroid or an increased dose of the current corticosteroids used as stand-alone therapy', 'or in combination. Rescue therapy is permitted for patients experiencing protocol-defined', 'MG clinical deterioration AND if, in addition, the treating physician believes that the', \"patient's health is in jeopardy if rescue therapy is not given. An MG clinical deterioration\", 'permitting rescue therapy to be given is defined as a patient experiencing at least one of the', 'argenx BVBA', 'Confidential', 'Page 53 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'following: (1) new or worsening of respiratory / bulbar symptoms or (2) at least 2-point', 'increase of individual non-ocular MG-ADL items. Whenever possible, prior to giving rescue', 'therapy to a patient, the Medical Director at the Sponsor and the Medical Monitor at the', \"Sponsor's designated Contract Research Organization (CRO) should be informed.\", 'In situations where the treatments as listed above are given under the protocol defined rescue', 'criteria, patients will be discontinued early from randomized treatment (see Section 4.4.2).', 'EARLY DISCONTINUATION FROM THE TRIAL', 'Any patient prematurely discontinuing the trial should perform the EoS/ED assessments.', 'EARLY DISCONTINUATION FROM RANDOMIZED TREATMENT', 'Patients who discontinue early from randomized treatment within a Treatment Cycle will', 'have to complete the End of Treatment (EoT) assessments and complete the remaining visits', 'in the current Treatment Cycle, according to the general schedule of assessments (SoA)', '(Table 1). These patients will not receive any further IMP administration during the trial and', 'will continue to be followed for safety and disease severity (limited to MG-ADL and QMG)', 'as per the SoA for Patients who Discontinued Early from Randomized Treatment (Table 2).', 'Patients who discontinue early from randomized treatment in the ITC period will have to', 'complete the EoT assessments and then continue into the Safety and Disease Severity', 'Follow-up period as per Table 2.', 'TEMPORARY INTERRUPTION FROM RANDOMIZED TREATMENT', 'A patient that does not need to be discontinued early from randomized treatment might still', 'have a temporary interruption from randomized treatment which is defined as a', 'discontinuation only from the current Treatment Cycle. Therefore, these patients might still', 'be eligible for further additional treatments with IMP within this trial.', 'A schematic of the trial design is presented in Figure 1.', '4.2.', 'Discussion of Trial Design', 'In the current trial, ARGX-113 will be administered in patients with gMG, with the aim to', 'evaluate the efficacy, safety, tolerability and quality of life of ARGX-113', 'This trial is designed as a randomized, double-blind, and placebo-controlled trial to', 'distinguish the effect of ARGX-113 from other influences such as placebo effect or biased', 'observation. The trial consists of a treatment part where all randomized patients will be', 'treated with the IMP and a re-treatment part where patients may be re-treated with the IMP', 'on an \"as needed basis\" in subsequent Treatment Cycles. The time between Treatment', 'Cycles is based on the duration of the treatment effect and may vary from patient to patient', 'and for each patient from cycle to cycle (patient-tailored approach).', 'argenx BVBA', 'Confidential', 'Page 54 of 110']\n\n###\n\n", "completion": "END"}